Antipsychotic effect of remoxipride, a new substituted benzamide with selective antidopaminergic activity.
Ten of 14 schizophrenic patients completed a 6-week pilot study with a new substituted benzamide, remoxipride. The final median dose was 600 mg/day (range 300-1200) corresponding to a plasma concentration of 5.16 mumol/l (1.55-11.50). Remoxipride reduced the psychotic symptomatology, especially hallucinations and delusions. The total Brief Psychiatric Rating Scale score decreased from 33.5 to 13.0 (P less than 0.01). Few side effects occurred; four patients had weak extrapyramidal symptoms, and four were slightly sedated. No cardiovascular side effects occurred. Prolactin increased, but apparently less than during sulpiride treatment.
D000328:Adult; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011388:Prolactin / Q000097:blood; D017330:Remoxipride; D012559:Schizophrenia / Q000188:drug therapy*
D001549:Benzamides; D017330:Remoxipride; D011388:Prolactin